A new drug to treat the "dry" form of macular degeneration is currently undergoing clinical trials.
Allegro Ophthalmics has reported encouraging results from the phase 2 study of Risuteganib.
The small phase 2 study involved 40 patients and was conducted over a 28 week period with participants receiving 2 injections. Half of the patients received two Risuteganib injections while the other half received a sham injection the first time and then an injection of the Risutenganib the second time. At the end of the trial, 48 percent of the patients receiving both Risuteganib injections had a gain of 8 letters in their visual acuity. In addition, there were no serious adverse side affects reported.
Dry macular degeneration can cause central vision loss and currently there is no treatment and is considered incurable. The dry form accounts for up to 90% of all cases of macular degeneration. Nutritional supplementation can help support macular degeneration and VisiVite offers several premium AREDS 2 supplements.*